1.. Introduction {#s1}
================

There are ∼10 different disorders that are classified as vasculitis (also known as angiitis). Vasculitis is a systemic autoimmune disease characterized by the chronic inflammation of systemic blood vessels, veins, and arteries of all types and sizes. This often causes symptoms that can rapidly induce death, such as the formation of blood clots (thrombosis), restriction of oxygenated blood supply (ischemia), and irreversible injury to affected organs.^[@DSN014C1]^ Although immune system disturbances appear to be the main cause of the disease, the pathogenesis of vasculitis is not fully understood. The diagnosis and treatment of vasculitis was recently greatly aided by the observation that three vasculitis disorders, namely Wegener\'s granulomatosis (WG), microscopic polyangiitis (MPA), and Churg--Strauss syndrome (CSS), are characterized by the presence of circulating antineutrophil cytoplasmic antibodies (ANCAs).^[@DSN014C2],[@DSN014C3]^ Two different types of ANCA have been identified. C-ANCA targets proteinase-3 and is most frequently found in WG, whereas P-ANCA, which targets myeloperoxidase, is most frequently detected in MPA and CSS. Consequently, enzyme immunosorbent assays (EIA) that examine the ability of patient serum to bind to these enzymes can be used to diagnose WG, MPA, and CSS. However, diagnoses made on the basis of positive EIAs will still need to be confirmed by biopsies. Moreover, many other vasculitis disorders are not characterized by the presence of ANCAs. Thus, the diagnosis of vasculitis disorders requires the identification of more convenient and generally applicable diagnostic markers. The identification of these markers may also provide insights into the pathogenesis behind this disorder and improve the therapy of vasculitis.

We have isolated putative gene markers that are characteristic to the autoimmune diseases, such as systemic lupus erythematodes (SLE)^[@DSN014C4]^ and rheumatoid arthritis (RA)^[@DSN014C5]^, using peripheral blood mononuclear cells (PBMCs). Here, we sought to identify new gene markers that can distinguish the autoimmune disease, in particular vasculitis, from other diseases with high specificity when PBMCs serve as the sample. For this purpose, we used the stepwise subtraction technique^[@DSN014C6]^ and high-density oligonucleotide microarrays to isolate those genes that show dramatically upregulated expression commonly in the pooled PBMC mRNAs of varieties of vasculitis patients regardless of the patient\'s symptom, active, or inactive phase when compared with normal volunteer PBMC mRNAs. To identify the genes that are upregulated in many vasculitis patients, we selected and mixed the PBMC mRNAs from patients with one of the following seven vasculitis disorders: WG, MPA, Takayasu\'s arteritis (TA), allergic granulomatous angiitis (AGA), malignant RA (MRA = rheumatoid vasculitis), giant cell arteritis (GCA), and polyarteritis nodosa (PN). We found that the following seven genes are commonly unpregulated in the PBMCs of many of these vasculitis patients regardless of their symptoms: early growth response 1 (*EGR1*), G0/G1 switch gene 2 (*G0S2*), hemoglobin delta (*HBD*), amphiregulin (also known as *AREG*), interleukin-1 receptor type II (*IL1R2*), *calgranulin C*, and a novel gene named *TVAS10*. Of these genes, we selected *G0S2* for further analysis because its physiological functions are poorly understood. We prepared anti-G0S2 antibodies and then generated G0S2 transgenic mice and examined their phenotype. We propose that the vasculitis gene markers we identified here may be useful for the future diagnosis of vasculitis.

2.. Materials and methods {#s2}
=========================

2.1.. Human subjects and ethical considerations {#s2a}
-----------------------------------------------

All systemic vasculitis patients used in this study were diagnosed according to a previously documented proposal (the ACR criteria and the CHCC criteria).^[@DSN014C1]^ This study was reviewed and approved by the Internal Review Board of the Research Institute for Microbial Diseases, Osaka University. Accordingly, written informed consent was obtained from all participants before their PBMCs were obtained. Serum samples were consecutively obtained regardless of the patient\'s symptom, active, or inactive phase.

2.2.. Statistical analysis {#s2b}
--------------------------

Significant differences were determined by using Mann--Whitney *U*-test (Figs. [1](#DSN014F1){ref-type="fig"} and [2](#DSN014F2){ref-type="fig"}B, [Supplementary Fig. S1](http://dnaresearch.oxfordjournals.org/cgi/content/full/dsn014/DC1)). The data are expressed as means ± SE. *P*-value of \<0.05 or \<0.01 was considered to be statistically significant.

![mRNA expression of selected *TAS/TAC* genes in the PBMCs from individual vasculitis patients and normal volunteers. qRT--PCR analyses show that (**A**) *EGR1* (*TAC-1*), (**B**) *G0S2* (*TAC-40*), (**C**) *HBD* (*TAC-106*), (**D**) *Amphiregulin* (*TAC-9*), and (**E**) *TVAS10* (*TAC-30*) are generally upregulated in the PBMCs of vasculitis patient (circles) but not in the PBMCs of normal volunteers (triangles). Each symbol denotes the mean value of a sample analyzed in triplicate. The leftmost filled circle signifies an RNA sample from the PBMCs of a healthy volunteer (male, age 52), which was used as a standard sample and whose expression level was set to 1.0. It allowed us to compare all of the expression profiles tested in this study. Average ± SE values of the vasculitis patient and normal volunteer groups are shown in the right-hand graphs and differ significantly (*P* \< 0.01).](dsn01401){#DSN014F1}

![Family tree of *G0S2* transgenic mice. (**A**) Of the 61 mice tested in the first trial, six *G0S2* transgenic mouse lines were generated. They all died except for the GTG1b line, which was not useful for further analysis because the human G0S2 gene was introduced on the Y chromosome; consequently, this mouse only produced male *G0S2* transgenic mice. (**B**) Of the 22 mice tested in the third trial, three *G0S2* transgenic mouse lines were generated. The only surviving GTG3a line is now under large scale propagation to establish a strain.](dsn01402){#DSN014F2}

2.3.. Transgene vector construction and production of G0S2 transgenic mice {#s2c}
--------------------------------------------------------------------------

To construct the transgene vector pCX-G0S2, the human G0S2 ORF was cloned from a SLE cDNA library^[@DSN014C4]^ by PCR with the *Eco*RI site-bearing primers G0S2-*Eco*RI-5\'F (5\'-TATGAATTCGCCACCATGGAAACGGTCCAGGAGCTGATC-3\') and G0S2-*Eco*RI-3\'R (5\'-ATAGAATTCCTAGGAGGCGTGCTGCCGGTTGGAC-3\'). The G0S2-*Eco*RI-5\'F primer contains the Kozak sequence ahead of the start codon of G0S2 cDNA, whereas the G0S2-*Eco*RI-3\'R primer contains the stop codon of G0S2 cDNA. The sequence of the amplified product was confirmed by DNA sequencing. As previously described,^[@DSN014C7]^ the *Eco*RI-digested fragment of the amplified G0S2 ORF was inserted into the *Eco*RI site of the pCAGGS expression vector, which possesses a chicken β-actin promoter and a cytomegalovirus enhancer (CMV-IE enhancer). The resulting construct was designated pCX-G0S2. To prepare the G0S2 fragment bearing the chicken β-actin promoter and the CMV-IE enhancer for injection into fertilized eggs, the *Sal*I/*Hin*dIII fragment of pCX-G0S2 was purified by electrophoresis and agarose gel extraction. The G0S2 transgenic embryos and mice were generated according to previously described protocols.^[@DSN014C7]^ Briefly, the purified DNA fragments were injected into B6D2F1× B6D2F1 fertilized eggs. The incorporation of the transgene was examined by the genomic PCR analysis using DNA extracted from the tail and the pCX-G0S2-1685F (5\'-GCTGGTTGTTGTGCTGTCTCATCA-3\') and pCX-G0S2-2161R (5\'-GCCAGAAGTCAGATGCTCAAGGGGCTTCA-3\') primers. The PCR conditions involved TaKaRa Ex *Taq* polymerase (Takara, Shiga, Japan) and a pre-heating step (95°C for 2 min), 30 reaction step cycles (95°C for 30 s, 58°C for 30 s, 72°C for 1 min), and a final elongation step (72°C for 5 min). The founder mice were mated with C57BL/6 mice and both the transmittance of the transgene and the successful expression of human G0S2 protein were examined by western blot analysis of total cell extracts of mouse tails using one of the anti-G0S2 monoclonal antibodies (clone \#3-1) we generated (see section 3.4 and [Supplementary Fig. S2](http://dnaresearch.oxfordjournals.org/cgi/content/full/dsn014/DC1)).

2.4.. Histological examination {#s2d}
------------------------------

C57BL/6 mice were purchased from Japan SLC (Hamamatsu, Japan). Mouse tissues were fixed immediately after removal with 4% paraformaldehyde, then embedded in paraffin, and cut into sections (4 µm thick). Some sections were stained with hematoxiln and eosin according to standard procedures, whereas others were stained with the clone \#3-1 monoclonal anti-G0S2 antibody according to the previously described procedure.^[@DSN014C8]^ To evaluate the immunostain, sections of the same organs from G0S2-TG and C57BL/6 mice were processed at the same time. When the immunoreactive signals in the former sections were substantially stronger than those in the latter, they were considered to indicate the exogenic G0S2 proteins produced from the transgene.

2.5.. In situ hybridization {#s2e}
---------------------------

Sections were processed in the Genostaff laboratory (Tokyo, Japan) by using the DIG RNA labeling and detection kits (Roche Diagnostics, Mannheim, Germany). Briefly, G0S2 antisense and sense (negative control) RNA probes were prepared by *in vitro* transcription of the pBluescript vector containing the full-length human G0S2 cDNA according to the manufacturer\'s instructions. Hybridized signals were colored blue with 4-nitro blue tetrazolium chloride and 5-bromo-4-chloro-3-indolyl-phosphate as a substrate of alkaline phosphatase. The sense probe did not yield any significant stains. Further information concerning the *in situ* hybridization (ISH) method is available on request.

2.6.. Serologic examination {#s2f}
---------------------------

Approximately 200 µl of peripheral blood per mouse were collected from the orbital plexus under anesthesia and were left for 1 h to coagulate. After centrifugation, ∼20 µl sera were obtained. The sera were frozen at −20°C and sent to the Mitsubishi Kagaku BCL laboratory (Tokyo, Japan), where each serum was diluted 500 times and analyzed for the levels of anti-nuclear and anti-double strand (ds) DNA antibodies by fluorescent antibody tests or enzyme immunoassays.

3.. Results {#s3}
===========

3.1.. Identification of vasculitis-specific genes by stepwise subtraction and DNA microarray analysis {#s3a}
-----------------------------------------------------------------------------------------------------

To isolate the putative vasculitis-specific genes that are commonly upregulated in the PBMCs of vasculitis patients, we first used our stepwise subtractive hybridization method. PBMC samples were obtained from vasculitis patients (50 patients in total) regardless of the patient\'s symptom, active, or inactive phase, and a cDNA library was prepared from their pooled mRNAs by the linker-primer method using a pAP3neo vector.^[@DSN014C9]^ Stepwise subtractive hybridization was then performed using the biotinylated pooled mRNAs from the PBMCs of eight normal volunteers, as described previously.^[@DSN014C6]^ This generated a library of genes that are upregulated in only vasculitis PBMCs. To examine whether these genes are actually upregulated in vasculitis but not normal PBMCs, we performed northern blot analysis using the pooled mRNAs from the vasculitis and normal PBMCs (Fig. [3](#DSN014F3){ref-type="fig"}A). For the cDNA clones whose expression levels were too low for detection by northern blot analysis, we examined their expression in vasculitis and normal PBMCs by RT--PCR (Fig. [3](#DSN014F3){ref-type="fig"}B). The 29 genes that were confirmed to be upregulated in vasculitis patients were called *TAS* after transcript augmented in vasculitis isolated by stepwise-subtraction. The *TAS* genes and their accession numbers are summarized in Table [1](#DSN014TB1){ref-type="table"}.

![mRNA expression levels of the *TAS* genes. Individual *TAS* genes were subjected to northern blot (**A**) or RT--PCR (**B**) analysis to confirm they are upregulated in the PBMCs of 50 vasculitis patients (A) but not in the PBMCs of eight normal volunteers (N). Table [1](#DSN014TB1){ref-type="table"} provides the names of the *TAS* genes. *GAPDH* was also analyzed as a loading control. The annealing temperature for RT--PCR was always 58°C and amplification occurred over 30 cycles. The sequences of the primers used to identify the *TAS* genes are presented in [Supplementary Table S1](http://dnaresearch.oxfordjournals.org/cgi/content/full/dsn014/DC1).](dsn01403){#DSN014F3}

###### 

List of stepwise subtraction identified *TAS* genes that show upregulated expression in vasculitis patient PBMCs

  Gene name           Accession number   Sequence description
  ------------------- ------------------ ---------------------------------------------------------------------
  *TAS1-120*          AK091533           Unknown (sapiens cDNA FLJ34214) = *TVAS1*
  *TAS1-126*          NM_006013          Ribosomal protein L10 (RPL10)
  *[TAS1-137]{.ul}*   AC007318           Unknown (AL049356) = *TVAS2*
  *[TAS1-140]{.ul}*   BC033089           Lipocalin 2 (oncogene 24p3)
  *TAS1-149*          BC008684           Similar to splicing factor, arginine/serine-rich (MGC:9742)
  *TAS1-160*          NM_016304          Unknown (C15orf15) = *TVAS3*
  *[TAS1-198]{.ul}*   BC010878           ASF1 anti-silencing function 1 homolog A
  *TAS1-267*          BC042436           Unknown (IMAGE:4471726) = *TVAS4*
  *[TAS1-377]{.ul}*   AY275537           Unknown (isolate 183 mitochondrion) = *TVAS5*
  *[TAS2-047]{.ul}*   BC047681           S100 calcium binding protein A9 (calgranulin B)
  *[TAS2-078]{.ul}*   NM_004417          Dual specificity phosphatase 1 (DUSP1)
  *TAS2-097*          D89974             Glycosylphosphatidyl inositol-anchored protein GPI-80
  *TAS3-032*          NM_015384          Nipped-B homolog (*Drosophila*) (NIPBL)
  *TAS3-039*          NM_001030          Ribosomal protein S27 (metallopanstimulin 1) (RPS27)
  *TAS3-046*          BC000927           Poly(A) polymerase alpha
  *TAS3-047*          NM_000517          Hemoglobin, alpha 2 (HBA2)
  *[TAS3-053]{.ul}*   NM_004633          Interleukin 1 receptor, type II (IL1R2)(AY124010)
  *[TAS3-062]{.ul}*   BC000163           Vimentin
  *[TAS3-076]{.ul}*   BC064910           Beta-2-microglobulin
  *[TAS3-079]{.ul}*   BC001429           Annexin A5
  *TAS3-112*          AY195792           Unknown (haplotype As9Y mitochondrion) = *TVAS6*
  *[TAS3-133]{.ul}*   NM_005870          Sin3-associated polypeptide, 18kDa (SAP18)
  *TAS3-135*          BC018183           NADH dehydrogenase (ubiquinone) 1 beta subcomplex
  *TAS4-011*          CR611844           Unknown (CS0DL007YO12 of B cells) = *TVAS7*
  *TAS1-171*          AY260957           Insulin-like growth factor 1 (somatomedin C) (IGF1)
  *[TAS1-191]{.ul}*   NM_005621          S100 calcium-binding protein A12 (calgranulin C)
  *TAS1-272*          NM_003805          CASP2 and RIPK1 domain containing adaptor with death domain (CRADD)
  *TAS1-274*          NM_004592          Splicing factor, arginine/serine-rich 8 (SFRS8)
  *TAS1-301*          BC062616           Protein serine kinase H1

The expression levels of the *TAS* genes were examined by northern blot (Fig. [1](#DSN014F1){ref-type="fig"}A) and/or RT--PCR (Fig. [1](#DSN014F1){ref-type="fig"}B). The underlined genes were subjected to qRT--PCR to determine their generality of expression in vasculitis patients but not normal volunteers (Fig. [3](#DSN014F3){ref-type="fig"}).

To increase the number of putative vasculitis-specific genes, we also performed a genome-wide complementary DNA microarray analysis using the Agilent Hu44K array with the same pooled vasculitis and normal PBMC RNA samples. When we tested the top 402 genes from the microarray list of vasculitis-upregulated genes (data not shown) by RT--PCR, we identified 63 genes whose expression levels are dramatically upregulated in vasculitis patient PBMCs (Fig. [4](#DSN014F4){ref-type="fig"}). We called them *TAC* after transcript augmented in vasculitis isolated by cDNA-microarray. The *TAC* genes and their accession numbers are summarized in Table [2](#DSN014TB2){ref-type="table"}. Dual specificity phosphatase 1 (*DUSP1*) and *IL1R2* were identified by both methods. Of the 92 *TAS* and *TAC* genes, 30 genes are uncharacterized genes. These are designated as *TVAS* after transcript increased in vasculitis.

![mRNA expression levels of the *TAC* genes. Individual *TAC* genes were subjected to RT--PCR analysis to confirm they are upregulated in the PBMCs of 50 vasculitis patients (A) but not in the PBMCs of eight normal volunteers (N). GAPDH was also analyzed as a loading control. The annealing temperature and amplification cycles for RT--PCR were always 50°C and 35 cycles, respectively, with the exception of the reactions denoted by a (55°C, 40 cycles), b (50°C, 30 cycles), c (58°C, 27 cycles), d (50°C, 40 cycles), and e (58°C, 30 cycles). The sequences of the primers used to identify the *TAS* genes are presented in [Supplementary Table S1](http://dnaresearch.oxfordjournals.org/cgi/content/full/dsn014/DC1).](dsn01404){#DSN014F4}

###### 

List of microarray identified *TAC* genes that show upregulated expression in the PBMCs of vasculitis patients

  Gene name          Accession number   Sequence description
  ------------------ ------------------ ---------------------------------------------------------------------
  *[TAC-1]{.ul}*     NM_001964          Early growth response 1 (EGR1) gene product
  *[TAC-2]{.ul}*     AK025198           Unknown (FLJ21545) = *TVAS8*
  *[TAC-3]{.ul}*     NM_000584          Interleukin 8 (IL8)
  *[TAC-9]{.ul}*     NM_001657          Amphiregulin
  *[TAC-14]{.ul}*    NM_003596          Tyrosylprotein sulfotransferase 1 (TPST1)
  *[TAC-19]{.ul}*    NM_004633          Interleukin 1 receptor, type II (IL1R2)
  *[TAC-28]{.ul}*    NM_000715          Complement component 4 binding protein, alpha (C4BPA)
  *TAC-29*           NM_017762          Unknown (FLJ20313) = *TVAS9*
  *[TAC-30]{.ul}*    NM_144590          Unknown (ankyrin repeat domain 22: MGC22805) = *TVAS10*
  *[TAC-31]{.ul}*    BC013734           Prostaglandin-endoperoxide synthase 2
  *[TAC-36]{.ul}*    AB044805           6-phosphofructo-2-kinase heart isoform
  *TAC-37*           NM_001511          Chemokine (C-X-C motif) ligand 1 (CXCL1)
  *[TAC-40]{.ul}*    NM_015714          G0/G1 switch gene 2 (G0S2)
  *TAC-43*           NM_004545          NADH dehydrogenase (ubiquinone) 1 beta (NDUFB1)
  *[TAC-47]{.ul}*    NM_080657          Viperin (cig5)
  *TAC-54*           BC029495           Unknown (MGC:33104) = *TVAS11*
  *TAC-55*           AF249277           Cervical cancer suppressor-1
  *TAC-61*           BC065737           Unknown (IMAGE:30404477) = *TVAS12*
  *TAC-64*           NM_000032          Aminolevulinate, delta-, synthase 2 (ALAS2)
  *TAC-77*           NM_000661          Ribosomal protein L9 (RPL9)
  *TAC-78*           NM_004233          CD83 antigen (immunoglobulin superfamily)
  *TAC-84*           X60364             ALAS mRNA for 5-aminolevulinate synthase precursor
  *TAC-85*           AK098605           Unknown (FLJ25739) = *TVAS13*
  *TAC-89*           NM_004833          Absent in melanoma 2 (AIM2)
  *TAC-91*           NM_001738          Carbonic anhydrase I (CA1)
  *TAC-102*          NM_005143          Haptoglobin (HP)
  *[TAC-106]{.ul}*   BQ446275           Hemoglobin delta (HBD)
  *TAC-115*          NM_182522          TAFA4 protein (TAFA4)
  *TAC-118*          L03419             Fc-gamma receptor I B1
  *[TAC-127]{.ul}*   NM_007115          Tumor necrosis factor, alpha-induced protein 6 (TNFAIP6)
  *TAC-141*          BX537874           Unknown (DKFZp313P036) = *TVAS14*
  *TAC-167*          BQ674642           Unknown = *TVAS15*
  *TAC-172*          AL390162           Unknown (DKFZp761A1916) = *TVAS16*
  *TAC-190*          NR_001459          Unknown (C14orf62) = *TVAS17*
  *TAC-191*          NM_002983          Chemokine (C-C motif) ligand 3 (CCL3)
  *TAC-226*          BC031359           Unknown (IMAGE:4778855) = *TVAS18*
  *TAC-229*          NM_002064          Glutaredoxin (thioltransferase) (GLRX)
  *TAC-234*          NM_000963          Prostaglandin G/H synthase and cyclooxygenase (PTGS2)
  *TAC-236*          NM_001124          Adrenomedullin (ADM)
  *TAC-237*          NM_014320          Heme-binding protein 2 (HEBP2)
  *TAC-242*          AW901958           Unknown = *TVAS19*
  *TAC-252*          NM_003096          Small nuclear ribonucleoprotein polypeptide G (SNRPG)
  *TAC-261*          NM_014879          G protein-coupled receptor 105 (GPR105)
  *TAC-266*          BC032663           Phorbol-12-myristate-13-acetate-induced protein 1
  *TAC-269*          BC032480           Unknown (IMAGE:5214272) = *TVAS20*
  *TAC-273*          NM_182619          Secretory protein LOC348174 (LOC348174)
  *TAC-274*          NM_012472          Testis specific leucine rich repeat protein (TSLRP)
  *TAC-275*          AX721252           Unknown (Patent WO0220754) = *TVAS21*
  *TAC-287*          NM_032412          Putative nuclear protein (ORF1-FL49)
  *TAC-295*          NM_024850          Butyrophilin-like 8 (BTNL8)
  *TAC-302*          BC005984           Unknown (IMAGE:4247211) = *TVAS22*
  *TAC-304*          NM_033655          Unknown = *TVAS23*
  *TAC-307*          BC042517           Unknown (IMAGE:4822953) = *TVAS24*
  *TAC-321*          AL831953           Unknown (DKFZp667P0410) = *TVAS25*
  *TAC-322*          AK128746           Unknown (FLJ44672) = *TVAS26*
  *TAC-324*          AF067801           Unknown (HDCGC21P) = *TVAS27*
  *TAC-330*          D86962             Unknown (KIAA0207) = *TVAS28*
  *[TAC-343]{.ul}*   NM_004417          Dual specificity phosphatase 1 (DUSP1)
  *TAC-353*          M64109             Udulin 2
  *TAC-357*          BC053669           Unknown (IMAGE:6146402) = *TVAS29*
  *TAC-374*          NM_016220          Zinc finger protein (ZFD25)
  *TAC-389*          NM_001955          Endothelin 1 (EDN1)
  *TAC-398*          NM_020995          Haptoglobin-related protein (HPR)
  *TAC-401*          NM_001161          Nudix (nucleoside diphosphate linked moiety X)-type motif 2 (NUDT2)
  *TAC-402*          AY358224           Unknown (UNQ9368) = *TVAS30*

The expression levels were examined by RT--PCR (Fig. [2](#DSN014F2){ref-type="fig"}). The underlined genes were subjected to qRT--PCR to determine their generality of expression in vasculitis patients but not normal volunteers (Fig. [3](#DSN014F3){ref-type="fig"}).

3.2.. Expression profiles of vasculitis-upregulated genes in individual patients {#s3b}
--------------------------------------------------------------------------------

To determine whether these vasculitis-specific candidate genes are indeed upregulated in patients suffering from WG, MPA, TA, AGA, MRA, GCA, or PN and thus are general markers of vasculitis, we subjected 25 of the *TAS* and *TAC* genes (underlined in Tables [1](#DSN014TB1){ref-type="table"} and [2](#DSN014TB2){ref-type="table"}) to quantitative RT--PCR (qRT--PCR) using PBMC RNA samples from indicated numbers of individual vasculitis patients and normal volunteers as negative controls (Fig. [1](#DSN014F1){ref-type="fig"} and [Supplementary Fig. S1](http://dnaresearch.oxfordjournals.org/cgi/content/full/dsn014/DC1)). In every qRT--PCR, a standard RNA (denoted as normal with a relative intensity of 1.0) from the PBMCs of a healthy volunteer (male, age 52) was used (see the leftmost filled circle in Fig. [1](#DSN014F1){ref-type="fig"}A--E); this allowed us to compare the expression profiles of the genes tested in this study. It also allowed us to compare the expression profiles of the genes in this study with those of other genes tested in our previous studies on SLE^[@DSN014C4]^ and RA.^[@DSN014C5]^ With this experiment, we expected to isolate those genes that are highly expressed not only in many vasculitis patients but also in patients with SLE^[@DSN014C4]^ and RA;^[@DSN014C5]^ the identification of such marker genes may be useful as sensitive and specific diagnostic tools.

Of the 25 *TAS/TAC* genes tested, *TAC-1* \[early growth responses 1 (*EGR1*)\] was one of the most strongly upregulated genes commonly in the PBMCs of many vasculitis patients, as 96% of patients expressed this gene at 3--300-fold higher levels than healthy volunteers (Fig. [1](#DSN014F1){ref-type="fig"}A). *EGR1* encodes a zinc finger transcription factor whose expression is induced within minutes upon the reception of growth stimuli; its expression then decays within a few hours. It promotes cellular differentiation along a macrophage lineage.^[@DSN014C10]^ It also plays a critical role in the response to both acute and chronic vascular stress by inducing the expression of several gene products linked to cellular perturbation. This is particularly true for the cellular perturbation in the vasculature that is induced by hypoxia, ischemia/reperfusion, atherosclerosis, and acute vascular injury.^[@DSN014C11]^ It remains unclear whether the induction of *EGR1* in vasculitis is a pathogenic response or merely results from vascular stress. Nonetheless, *EGR1* may serve as a gene marker for the diagnosis of vasculitis.

*TAC-40* (*G0S2*) is a lymphocyte G0/G1 switch gene that encodes a putative cell cycle inhibitor whose expression may be required before cells become committed to enter the G1 phase of the cell cycle.^[@DSN014C12]^ Nearly, half of the vasculitis patients showed \>20-fold increased expression, whereas the expression of most of the normal volunteers was much lower (Fig. [1](#DSN014F1){ref-type="fig"}B). Notably, relative to healthy controls, *G0S2* expression is also enhanced in the PBMCs from patients with other autoimmune diseases, namely SLE^[@DSN014C4]^ and RA.^[@DSN014C5]^ Microarray and qRT--PCR analyses also showed that *G0S2* is upregulated in the PBMCs from psoriasis patients suffering from severe generalized disease.^[@DSN014C13]^ Thus, it may be interesting to analyze *G0S2* further, as it may shed light on the pathogenesis of vasculitis at the molecular level (see below).

Nearly 77% of the vasculitis patients expressed 3--16-fold more *TAC-106* (*HBD*) mRNA than the normal volunteers (Fig. [1](#DSN014F1){ref-type="fig"}C). HBD is a minor type of hemoglobin (it makes up only 2--3% of adult hemoglobin) that forms a complex with α-hemoglobin called hemoglobin A~2~ (α~2~δ~2~).^[@DSN014C14]^ Although high HbA2 levels are diagnostic for the β-thalassemia trait, its relevance to vasculitis pathology is unknown. Nonetheless, it may be useful as a diagnostic gene marker for vasculitis.

Amphiregulin is one of the epidermal growth factor (EGF)-like growth factors that stimulate cell growth by activating the EGF receptor signaling of target cells in an autocrine/juxtacrine fashion.^[@DSN014C15]^ We previously reported that *Amphiregulin* expression is enhanced in the PBMCs of some patients with SLE^[@DSN014C4]^ and RA.^[@DSN014C5]^ However, compared with SLE and RA patients, a far smaller proportion of vasculitis patients show enhanced *Amphiregulin* expression (Fig. [1](#DSN014F1){ref-type="fig"}D). Thus, *Amphiregulin* may be more significant as a DNA marker for SLE and RA than for vasculitis.

*TAC30* (=*TVAS10*) encodes an uncharacterized novel protein that is composed primarily of an ankyrin repeat, which is one of the most frequently observed amino-acid motifs and is important for protein--protein interactions.^[@DSN014C16]^ About a half of the vasculitis patients showed 10--200-fold increased expression of *TAC30*, whereas healthy volunteers showed very low expression except for one case (Fig. [1](#DSN014F1){ref-type="fig"}E).

Interleukin-1 (IL1), a principal macrophage-derived cytokine, plays a pivotal role in the immuno-inflammatory process by triggering cell activation *via* its type I receptor (IL1R1); in contrast, its type II receptor (IL1R2) lacks the intracellular domain for IL1 signaling and functions as a potent, specific, and natural inhibitor of IL1 by acting as a decoy receptor.^[@DSN014C17]^ About half of the vasculitis patients showed 20--50-fold *IL1R2* expression (one patient showed ∼300-fold expression), whereas healthy volunteers showed very low expression except for one case ([Supplementary Fig. S1A](http://dnaresearch.oxfordjournals.org/cgi/content/full/dsn014/DC1)). This increased expression of IL1R2 may be related to the vascular inflammation of the vasculitis patients.

Three phagocyte-specific S100 proteins called calgranulin- A, -B, and -C act separately during calcium-dependent signaling. In particular, *TAS1-191* (*calgranulin C*) secretion by tumor necrosis factor (TNF)- stimulated granulocytes causes target cell activation that results in the upregulated expression of proinflammatory cytokines such as TNF and IL1β; the TNF that is released may then stimulate granulocytes to secrete more calgranulin C, thereby establishing a self-amplifying positive feedback loop.^[@DSN014C18]^ About 30% of vasculitis patients showed 10--50-fold *calgranulin C* expression (one patient showed ∼150-fold expression), whereas most of the healthy volunteers showed low expression ([Supplementary Fig. S1B](http://dnaresearch.oxfordjournals.org/cgi/content/full/dsn014/DC1)). In contrast, the vasculitis patients and normal volunteers did not differ in their expression of *calgranulin B* (*TAS2-047*) (data not shown).

3.3.. Expression pattern of TAS/TAC genes in PBMC {#s3c}
-------------------------------------------------

We previously reported that *G0S2* was primarily expressed in monocytes, whereas *Amphiregulin* was expressed in both monocytes, T cells and B cells by performing RT--PCR on multiple-tissue cDNA panels (MTC) from Clontech (Palo Alto, CA).^[@DSN014C5]^ To determine whether *EGR1*, *HBD*, *TVAS10*, *IL1R2*, and *calgranulin C* are also expressed in particular human blood cells, we conducted similar experiments. As shown in Fig. [5](#DSN014F5){ref-type="fig"}, *EGR1* and *IL1R2* were expressed ubiquitously in all lanes, albeit with varying intensities. cDNA from placenta, which also contains many blood cells, served as a control. All genes except *calgranulin C* were strongly expressed in activated CD4^+^ T cells (lane 8) and weakly expressed in activated mononuclear cells (aMNCs) (lane 7). Only *EGR1* and *TVAS10* were expressed in activated CD8^+^ T (lane 9) cells. *EGR1*, *TVAS10*, *IL1R2*, and *calgranulin C* were expressed in resting CD8^+^ T cells (T-suppressor/cytotoxic; lane 2) and monocytes (lane 4). These observations together indicate that these vasculitis-upregulated genes have similar expression profiles. Unfortunately, we could not perform this analysis on vasculitis patients because of the low numbers of PBMCs that we could obtain from the patients.

![Determination of the human blood cells that express *EGR1*, *HBD*, *TVAS10*, *IL1R2*, and *calgranulin C* (*Cal C*). RT--PCR was performed by using the multiple-tissue cDNA panel for human blood fractions (MTC, Clontech)*. GAPDH* was also amplified as a loading control. PCR amplifications were conducted at 50°C over 33 cycles except as indicated at the right of the panels by \# (50°C over 30 cycles). Lane 1, mononuclear cells (B, T cells, and monocytes). Lane 2, resting CD8+ cells (T-suppressor/cytotoxic cells). Lane 3, resting CD4+ cells (T-helper/inducer). Lane 4, resting CD14+ cells (monocytes). Lane 5, resting CD19+ cells (B cells). Lane 6, activated CD19+ cells (aCD10 +). Lane 7, activated mononuclear cells (aMNC). Lane 8, activated CD4+ cells (aCD8 + ). Lane 9, activated CD8+ cells. Lane 10, human placenta, which also includes many blood cells. The latter lane served as a control.](dsn01405){#DSN014F5}

3.4.. Preparation of transgenic mice that overexpress G0S2 {#s3d}
----------------------------------------------------------

We selected G0S2 for further analysis because little is known about its physiological significance and function. To explore the physiological significance of G0S2, we prepared transgenic mice that overexpress the human gene for G0S2. For this purpose, we constructed plasmid DNA in which human G0S2 cDNA lies directly downstream of the beta-actin promoter, as described previously.^[@DSN014C7]^ This construct was used to generate transgenic mouse lines that express human G0S2 protein in all tissues. The successful generation of these transgenic mice was confirmed by PCR and/or western blot analysis using DNA or cell extracts obtained from the tail. Expression of G0S2 protein was confirmed by the monoclonal antibody (\#3-1) we prepared here (see [Supplementary Result and Fig. S2](http://dnaresearch.oxfordjournals.org/cgi/content/full/dsn014/DC1)). Although the transgenic mice did not exhibit an obvious phenotype, they seemed to be unhealthy as they did not produce large numbers of offspring. This made it very difficult to establish this transgenic mouse line. For example, in the first attempt to generate this line, 61 mice were tested by PCR for expression of human G0S2. Of these, three female and three male mice were found to bear the transgene (GTG1a-f, see Fig. [2](#DSN014F2){ref-type="fig"}). However, the GTG1f female mouse died soon after birth and the GTG1e female and GTG1c male mice died 3 and 1 months after birth, respectively ([Supplementary Fig. S4A](http://dnaresearch.oxfordjournals.org/cgi/content/full/dsn014/DC1)). Moreover, while the surviving female transgenic mouse (GTG1d) produced one female transgenic mouse, which safely grew to adulthood, the mother died during her next pregnancy. Her daughter also died during her first pregnancy. In addition, the surviving male mouse GTG1b only produced male transgenic mice when mated with wild-type B6 female mice because the human G0S2 gene was introduced into the Y chromosome. Thus, this mouse could not be used further. Furthermore, the remaining surviving male mouse, GTG1a, did not produce transgenic mouse when mated with wild-type B6 female mice. Thus, we failed to establish a human G0S2-expressing transgenic strain in this trial. The second trial did not generate any transgenic mice. However, in the third trial, of the 22 mice examined by PCR (Fig. [6](#DSN014F6){ref-type="fig"}A) and western blot analysis (Fig. [6](#DSN014F6){ref-type="fig"}B), we found three transgenic mice, of which one (GTG3a) produced offspring (see [Supplementary Fig. S4B](http://dnaresearch.oxfordjournals.org/cgi/content/full/dsn014/DC1)). These mice appear to be healthier than the other transgenic mice and consequently we have been able to maintain this line probably due to lower G0S2 levels than other transgenic mice. Thus, the exogenous and ubiquitous overexpression of human G0S2 seems to make the transgenic mice unhealthy and inhibits their production of offspring.

![Establishment of *G0S2* transgenic mice. (**A**) An example of the RT--PCR analyses used to identify *G0S2* transgenic mice. (**B**) Western blot analysis to identify *G0S2* transgenic mice. The panel for ATG3-F1 and -F2 mice is shown as an example. The transgenic mouse numbers are underlined. (**C**) ISH analyses of G0S2-TG mice. Sections from the kidney (i), stomach (ii, mucosa; v, smooth muscle), esophagus (iii), heart (iv), and epididymis (vi) of adult G0S2-TG mice (GTG1b is shown as an example) were hybridized with the human G0S2 antisense probe and colored blue by using the alkaline phosphatase reaction. The nuclei were counterstained with nuclear fast red. Original magnification: ×200. (**D**) Immunological detection of exogenic G0S2 proteins in various organs of G0S2-TG mice (GTG1b is shown as an example). Sections from the kidney (i), stomach (ii), lung (iii), and heart (iv) of the adult G0S2-TG mice were incubated with the mouse monoclonal anti-G0S2 antibody (\#3-1) and stained with diaminobenzidine. The nuclei were counterstained with hematoxylin. Original magnification: **A** and **B**, ×200; **C** and **D**, ×400.](dsn01406){#DSN014F6}

3.5.. Human G0S2 expression patterns in transgenic mice {#s3e}
-------------------------------------------------------

To examine the expression patterns of exogenous human G0S2 in various transgenic mouse tissues, we first performed ISH analysis. As shown in some representative pictures (Fig. [6](#DSN014F6){ref-type="fig"}C), high-level expression of *G0S2* mRNA was detected in various organs and tissues. The signals in the urinary tubule, gastric foveola, and esophageal mucosa were distributed in epithelial clumps (Fig. [6](#DSN014F6){ref-type="fig"}Ci--iii). In contrast, scattered or diffusely distributed signals were detected in the cardiac ventricle, gastric smooth muscle, and seminiferous tubule (Fig. [6](#DSN014F6){ref-type="fig"}Civ--vi).

Immunohistochemical analysis using the monoclonal antibody (\#3-1) also detected exogenously expressed human G0S2 proteins in various organs and tissues of the transgenic mice. As shown in some representative pictures (Fig. [6](#DSN014F6){ref-type="fig"}D), the cellular distribution pattern of these proteins was similar to that of exogenous *G0S2* mRNA (Fig. [6](#DSN014F6){ref-type="fig"}C). In the kidney, although most urinary tubule epithelia were weakly positive for G0S2, other epithelia expressed this protein at high levels; the latter epithelia also existed in clumps (Fig. [6](#DSN014F6){ref-type="fig"}Di). A similar patchy distribution of strong G0S2 signals was detected in the foveolar epithelia of the stomach (Fig. [6](#DSN014F6){ref-type="fig"}Dii). In the lung and heart, there was a scattered distribution of exogenous G0S2 signals in the alveolar epithelium and a diffuse distribution in cardiac ventricular muscle, respectively (Fig. [6](#DSN014F6){ref-type="fig"}Diii and iv).

3.6.. Phenotypes of G0S2 transgenic mice {#s3f}
----------------------------------------

To explore the phenotypes of the G0S2 transgenic mouse, we first subjected various organs of G0S2 transgenic mice and wild-type (C57BL/6) mice to histological examination. Obvious histopathological findings that related directly to vasculitis were not observed. Notably, microabscess-like panniculitis lesions were detected in the dermis and subcutaneous fat tissue (Fig. [7](#DSN014F7){ref-type="fig"}A). Of the eight TG mice examined, such lesions were detected in three. We also measured the serum levels of two autoimmunity-related antibodies, namely, anti-nuclear antibody (ANA) and anti-dsDNA antibody. We found both were increased in G0S2 TG mice: the OD490 for ANA in the transgenic mice was 0.359 ± 0.170 \[compared with 0.219 ± 0.044 for wild-type (B6) mice\], whereas the OD490 for anti-dsDNA antibody was 0.294 ± 0.090 (compared with 0.188 ± 0.038 in wild-type mice) (Fig. [7](#DSN014F7){ref-type="fig"}B). However, these differences did not reach statistical significance, in part, because of the limited number of G0S2 TG mice we could use for these measurements. Taken together, it appears that G0S2 may participate in the pathogenesis of autoimmune diseases in general, and in particular, it may be related to inflammation.

![Histological and serological phenotypes of G0S2-TG mice. (**A**) Histological phenotype of G0S2-TG mice (GTG1b is shown as an example). Sections of the back skin of adult G0S2-TG mice were stained with hematoxylin and eosin. A boxed area in the left panel is enlarged in the right to show microabscess lesions containing numerous neutrophils. Original magnification: left, ×100; right, ×400. (**B**) Serological phenotypes of G0S2-TG mice (GTG1a is shown as an example). The sera from adult C57BL/6 (open circle) or G0S2-TG (closed circle) mice were examined for the levels of ANA and anti-dsDNA antibody. Asterisk and double asterisks indicate 'not significant' because *P* = 0.1011 and *P* = 0.0526, respectively, as determined by the Mann--Whitney *U*-test of differences between G0S2-TG and wild-type mice. The G0S2 TG mice examined are designated as follows: a (GTG1a), b (GTG1b), c (GTG1b-F1a), d (GTG1b-F2a), and e (GTG1b-F1c). The values of individual mice are plotted.](dsn01407){#DSN014F7}

4.. Discussion {#s4}
==============

In the present study, we report candidate gene markers for vasculitis that may be useful for diagnosing and understanding the basic pathogenesis of vasculitis and other autoimmune diseases such as SLE. These genes were identified by stepwise subtraction and cDNA microarray techniques, which permitted us to comprehensively isolate the genes that show augmented mRNA expression in the PBMCs of vasculitis patients when compared with normal volunteers. The vasculitis-specific upregulation of these genes was validated with northern blot and/or RT--PCR analyses (Figs [3](#DSN014F3){ref-type="fig"} and [4](#DSN014F4){ref-type="fig"}, Tables [1](#DSN014TB1){ref-type="table"} and [2](#DSN014TB2){ref-type="table"}). We then showed by RT--PCR analysis that *EGR1*, *G0S2*, *HBD*, *TVAS10*, *IL1R2*, *Amphiregulin*, and *calgranulin C* are frequently upregulated in the PBMCs of vasculitis patients (Fig. [1](#DSN014F1){ref-type="fig"} and [Supplementary Fig. S1](http://dnaresearch.oxfordjournals.org/cgi/content/full/dsn014/DC1)). MTC analysis revealed that in normal PBMCs, these genes are expressed primarily by monocytes and/or activated CD4+ cells (Fig. [5](#DSN014F5){ref-type="fig"}). We also showed previously using different primers and PCR conditions that *G0S2* is predominantly expressed by monocytes.^[@DSN014C5]^ These results suggest that monocytes, including macrophages, express these vasculitis-upregulated genes and thus may play a role in the pathogenesis of vasculitis.

We noticed that several putative vasculitis-upregulated genes also show upregulated expression in other autoimmune diseases, namely, SLE and RA (Table [3](#DSN014TB3){ref-type="table"}). Of these, *EGR1* is particularly interesting as the degree to which it is upregulated in most vasculitis patients is remarkable (Fig. [1](#DSN014F1){ref-type="fig"}A). *EGR1* is induced by a variety of cellular stresses, including hypoxia, and may function as a master switch that triggers the expression of numerous key inflammatory mediators. In particular, *EGR1* induces a number of gene products that have been linked to cellular perturbation, especially in the vasculature. Moreover, many of these genes are often induced in the PBMCs of patients afflicted with a variety of autoimmune diseases. For example, we showed previously that *EGR1* is markedly upregulated in the PBMCs of SLE patients.^[@DSN014C4]^ It also plays a critical role in promoting cellular differentiation along a macrophage lineage.^[@DSN014C10]^ Nonetheless, *EGR1*-null mice are viable and develop and grow normally.^[@DSN014C19]^ Rigorous analyses will be needed to determine whether the upregulation of *EGR1* mRNA in many vasculitis patients is pathogenically significant or merely an associated phenomenon.

###### 

List of the *TAC/TAS* genes that also show upregulated expression in PBMCs from SLE and RA patients

  Name              Vasculitis   SLE    RA     Sequence description
  ----------------- ------------ ------ ------ --------------------------------------------------
  *[TAC-1]{.ul}*    42.0         44.7   nc     Early growth response 1 (EGR1)
  *[TAC-2]{.ul}*    41.7         24.1   nc     Unknown (FLJ21545) = *TVAS8*
  *[TAC-3]{.ul}*    29.7         23.2   2.4    Interleukin 8 (IL8)
  *[TAC-9]{.ul}*    12.3         12.3   27.4   Amphiregulin
  *TAC-13*          9.7          11.3   1.8    CD69 antigen (early T-cell activation antigen)
  *[TAC-14]{.ul}*   9.4          7.2    3.9    Tyrosylprotein sulfotransferase 1 (TPST1)
  *[TAC-19]{.ul}*   9.1          5.3    9.4    Interleukin 1 receptor, type II (IL1R2)
  *TAC-20*          8.8          18.0   1.4    Similar to interferon alpha-inducible protein 27
  *TAC-34*          6.9          11.5   2.4    Sin3-associated polypeptide, 30kDa (SAP30)
  *TAC-37*          6.8          3.9    2.4    Chemokine (C-X-C motif) ligand 1 (CXCL1)
  *[TAC-40]{.ul}*   6.7          14.8   4.0    G0/G1 switch gene 2 (G0S2)
  *[TAC-47]{.ul}*   6.4          20.7   nc     Viperin (cig5)
  *TAC-51*          6.2          10.7   4.4    Nuclear factor of kappa B (NFκB)
  *TAC-78*          5.5          11.4   1.7    CD83 antigen (immunoglobulin superfamily)

The numbers represent fold change compared with normal volunteers; nc, no conspicuous change between RA and control.

*G0S2* also displayed enhanced expression in many vasculitis patients (Fig. [1](#DSN014F1){ref-type="fig"}B). *G0S2* was first identified as one of the G0/G1 switch (G0S) genes that are differentially expressed in lymphocytes during their lectin-induced switch from the G0 to the G1 phases of the cell cycle.^[@DSN014C20]^ *G0S2* is one of the genes that is upregulated during normal implantation but its expression is significantly lower in women with endometriosis that is associated with pelvic pain and infertility with implantation failure.^[@DSN014C21]^ In a replicative senescence model employing human dermal fibroblasts (HDF), *G0S2* expression was upregulated in old HDF cells, which suggests that it participates in senescence.^[@DSN014C22]^ Microarray and qRT--PCR analyses of PBMCs from psoriasis patients suffering from severe generalized disease also revealed the upregulation of *G0S2*.^[@DSN014C13]^ Moreover, we showed previously that *G0S2* mRNA levels are markedly increased in the PBMCs from patients with the autoimmune diseases SLE^[@DSN014C4]^ and RA.^[@DSN014C5]^ *G0S2* is a putative target gene of peroxisome-proliferator-activated receptor (PPAR) alpha, which belongs to a group of transcription factors that are involved in numerous processes, including lipid metabolism and adipogenesis. Moreover, it was shown that *G0S2* is upregulated after PPARδ activation and that it may be involved in the PPARδ-mediated mitigation of cardiac fibroblast proliferation.^[@DSN014C23]^

We here generated G0S2-TG mice that ubiquitously overexpress G0S2 proteins (Fig. [6](#DSN014F6){ref-type="fig"}). We showed that these mice are unhealthy as they do not produce many offspring (Fig. [2](#DSN014F2){ref-type="fig"}) and frequently display formations of microabscess-like panniculitis lesions in the dermis and subcutaneous fat tissue (Fig. [7](#DSN014F7){ref-type="fig"}A). The development of these microabscess-like panniculitis lesions may reflect the dysregulation of the murine immune system in these mice. Supporting this is that some of the G0S2-TG mice had augmented levels of immunodeficiency-related anti-nuclear and anti-dsDNA antibodies in their sera (Fig. [7](#DSN014F7){ref-type="fig"}B), although these phenotypes are related not to vasculitis but to SLE. It should be noted, however, that these serum differences did not achieve statistical significance, largely because of the shortage of G0S2-TG mice. It will be necessary to study larger numbers of G0S2-TG mice to confirm this association between *G0S2* overexpression and the development of autoimmune features. Should this association be confirmed, the high-quality polyclonal and monoclonal anti-G0S2 antibodies that we produced may be useful as tools (perhaps in enzyme-linked EIA) for diagnosing not just vasculitis but also other autoimmune diseases.

We performed this study on a highly heterogeneous cohort of patients, including those with systemic vasculitis. All of these diseases share the inflammatory involvement of blood vessels. However, their target organs, pathogenic mechanisms, clinical findings, and outcomes are quite different. Moreover, although the disease activity status in these patients was heterogeneous and some were receiving corticosteroid or immunosuppressive therapy, these factors were ignored in our patient recruitment protocol. Nonetheless, despite these marked heterogeneous features of our patient population, we could isolate putative common genes that are upregulated, which was our original goal. We are currently performing in parallel the expression profiling of the genes that are up- or downregulated in each individual disease and analyzing these profiles in terms of the symptoms, disease activity status, and clinical treatment of the patients. However, the results obtained from such studies are highly complex, which has hampered the identification of candidate gene markers that can be used for diagnosis.

Taken together, we conclude that the putative gene markers we identified here, in particular *EGR1* and *G0S2*, may be useful for diagnosing not only vasculitis but also other autoimmune diseases, perhaps by qRT--PCR and antibody-based methods. Other, as yet uncharacterized, genes that we detected as being upregulated in vasculitis may also be useful candidate gene markers and thus are worth further detailed analysis. In particular, the identification of the functions of these genes may reveal the hitherto unknown mechanism(s) that underlie the pathogenesis of vasculitis. This in turn may shed light on therapeutic avenues for treating vasculitis.
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